Bausch + Lomb acquired Whitecap Biosciences, which is developing two innovative treatments for glaucoma and geographic atrophy, considered an advanced form of age-related macular degeneration. According to the announcement, the acquisition aims to strengthen expanding clinical studies. Dr. Yehia Hashad, Vice President of Research and Development at Bausch + Lomb, said: “We are focused on significantly improving the current standard of care. For these two serious problems, Biosciences’ investigational medicines show real promise in slowing vision loss and perhaps even improving vision.”

January 2025